Arrowhead Pharma Q3 EPS $(0.96) Misses $(0.58) Estimate, Sales $15.82M Miss $48.19M Estimate
Portfolio Pulse from sunil@benzinga.com
Arrowhead Pharma reported Q3 losses of $(0.96) per share, missing the analyst consensus estimate of $(0.58) by 65.52%. The company also reported quarterly sales of $15.82 million, missing the analyst consensus estimate of $48.19 million by 67.16%. This represents a decrease in both earnings and sales compared to the same period last year.
August 07, 2023 | 8:10 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Arrowhead Pharma's Q3 earnings and sales missed analyst estimates, which could negatively impact the company's stock price in the short term.
Arrowhead Pharma's Q3 earnings and sales fell short of analyst estimates. This underperformance could lead to a decrease in investor confidence and a potential drop in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100